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Introduction 
Antiviral agents that block HIV-1 entry (entry inhibitors) are 
considered as an effective class of drugs and have been 
increasingly exploited in recent years.1-5 At present, only two of 
them members of this class have been clinically approved: 
Enfuvirtide (T20),6 a 36-mer water soluble peptide derived from 
the C-terminal heptad repeat region of gp41 and Maraviroc 
(MVC),7 which binds to the CCR5 co-receptor and inhibits HIV-1 
entry by blocking the gp120-CCR5 interaction. In addition, only 
VIRIP (VIRus-Inhibitory Peptide, natural peptide identified in 
human serum) has been reported to bind to the highly 
conserved hydrophobic gp41 fusion peptide of HIV-1 (FP23) 
preventing its insertion into the host cell membrane.8,9 
Previous studies support the hypothesis that the GB virus C 
(GBV-C) E1 protein interferes HIV-1 entry, being consequently 
considered as an attractive model peptide for the development 
of novel anti-HIV therapies.10 Particularly, our group has defined 
a new peptide lead, derived from the region (139-156) of the E1 
protein, as a HIV-1 entry inhibitor. This 18-mer synthetic peptide, 
namely E1P47, has demonstrated a broad spectrum of activity 
against HIV-1. Moreover, biochemical and biophysical assays 
such as a competitive ELISA using specific gp41-targeting mAbs, 
fluorescence resonance energy transfer as well as haemolysis 
assays have demonstrated that this E1 peptide sequence 
interacts with FP23.11 To get further insight into the features of 
E1P47 peptide inhibition mechanism it is necessary to 
understand the conformational profile of the inhibitor, how it 
inhibits HIV-1 entry (the binding mode) and to have structure-
activity information to identify the relevant structural elements 
for the E1P47 activity. Thus, specific information at atomic 
resolution on  E1P47 structure and the nature on the peptide-
peptide (E1P47-FP23) interactions obtained by Nuclear 
Magnetic Resonance (NMR) could lead to the characterization 
of the inhibition mechanism. 
There are a large number of studies about the structure of 
FP23 and its conformational changes associated to membrane 
fusion.12-15. One of the requirements for these studies is to do 
the measurements in conditions that mimics the membrane 
environment. Thus, it has been observed that the FP23 adopts 
different conformations that can be related to its physiological 
activity, depending on conditions such as the peptide-to-lipid 
molar ratio, membrane lipid composition (per example, the 
presence of cholesterol), the concentration of divalent cations, 
the pH and the amino acid sequence studied.16-20 Although, the 
use of dodecylphosphocholine (DPC) micelles for the 
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determination of peptide/protein structure in membrane 
environments by NMR spectroscopy was first described by 
Wüthrich and co-workers in early 80’s,21 there are few previously 
reported works which study by NMR the interaction between two 
peptides in lipid environment.22,23  
In this work, we focus on the characterization of E1P47 
structural features which are determinant for its biological activity 
and the study of the interaction of E1P47 peptide with the 
proposed FP23 viral target. Specifically, we report the structure 
of E1P47 peptide determined by NMR spectroscopy in DPC 
micelles solved using restrained molecular dynamics 
calculations. In parallel, by screening a library composed by 49 
variants of E1P47 peptide (both positional alanine scanning and 
truncated forms), we have studied the structure-activity 
relationship. Last, the acquisition of different NMR experiments 
in DPC micelles (peptide-peptide titration, diffusion NMR and 
addition of paramagnetic relaxation agents) allows the proposal 
of an inhibition mechanism for E1P47 peptide through 
interaction with FP23 at membrane level. Our data support the 
hypothesis that a peptide from non-pathogenic E1 GBV-C 
protein, with a helix-turn-helix structure, inhibits HIV-1 fusion by 
binding to FP23 peptide. 
Results and Discussion 
Antiviral effect of E1P47 related peptides 
 
To characterize the E1P47 peptide sequence features that could 
be related with its anti-HIV-1 activity a structure-activity study 
has been carried out. The previously obtained E1P47 analogues 
with restricted conformations demonstrated a loss of activity. 
Thus, disulphide cyclic as well as head-to-tail cyclic E1P47 
analogues were significantly less active than the linear peptide 
indicating that the addition of a constraint to the peptide 
sequence by means of a cyclic formation led to a fixed 
conformation that did not seem to fit the active site properly.10 In 
order to investigate the structural features that determine the 
activity of E1P47 peptide, truncated analogues from 17 to 8 
amino acid residues mapping the N- and C-terminus as well as 
the core of the primary sequence were synthesized on solid 
phase (Table S1, Supporting Information) and tested on HIV-1 
NL4-3 replication cellular assays (Materials and Methods in 
Supporting Information). Table 1 shows the primary sequence of 
the truncated peptides, their antiviral activities expressed as 
IC50 values and the highest not toxic concentrations. Most of 
the shorter peptides did not demonstrated anti-HIV-1 activity in 
the low micromolar range. The reduction of two residues either 
on N- or on C- terminus decreased the antiviral activity of the 
parent peptide sequence, which indicates that the shorter amino 
acid sequence that maintains the antiviral activity is almost the 
former 18-mer peptide.  
Besides, an alanine positional scanning was carried out to 
identify the amino acid residues that have a significant 
contribution to the antiviral activity and therefore might be 
involved in the interaction with the HIV-1 fusion peptide. Table 2 
shows the primary structure of the 18-mer analogues, their anti-
HIV activities and toxicities. These results demonstrated that the 
six N-terminal amino acids are essential for maintaining the 
antiviral activity since the substitution of each one by Ala 
determines the loss of activity. Moreover, the Pro and the Asp 
residues of the core region also contribute decisively to the anti-
HIV-1 activity. The substitution of the remaining positions by Ala 
did not dramatically change the activity of the peptide. Moreover, 
the synthesized scrambled peptide of E1P47 did not 
demonstrate any antiviral activity. 
 
Table 1. Inhibitory activity on HIV-1 NL4-3 infectivity assay of E1P47 truncated 
peptides. 
 
Primary sequence IC50 (µM) 
Toxicity 
(µM) 
WILEYLWKVPFDFWRGVI 5 >60 
N-truncated analogues 
 ILEYLWKVPFDFWRGVI 5 >100 
  LEYLWKVPFDFWRGVI 20 >100 
    EYLWKVPFDFWRGVI 50 >100 
      YLWKVPFDFWRGVI 50 >100 
         LWKVPFDFWRGVI 20 >100 
           WKVPFDFWRGVI - >100 
               KVPFDFWRGVI - >100 
                  VPFDFWRGVI - >100 
                     PFDFWRGVI - >100 
                       FDFWRGVI - >100 
Core-truncated analogues 
                  PFDFWRGV -  
                VPFDFWRG - >60 
              KVPFDFWR - >60 
          WKVPFDFW - >60 
        LWKVPFDF - >60 
      YLWKVPFD - >60 
    EYLWKVPF - >60 
  LEYLWKVP - >60 
 ILEYLWKV - >60 
C-truncated analogues 
WILEYLWK - >60 
WILEYLWKV  - >30 
WILEYLWKVP - >60 
WILEYLWKVPF - >60 
WILEYLWKVPFD - >60 
WILEYLWKVPFDF - >60 
WILEYLWKVPFDFW - >60 
WILEYLWKVPFDFWR 10  
WILEYLWKVPFDFWRG 25  
WILEYLWKVPFDFWRGV 10  
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Table 2. Inhibitory activity on HIV-1 NL4-3 infectivity assay of E1P47 alanine 
analogues. 
 
Primary sequence 
IC50 (µM) Toxicity 
(µM) 
Alanine Positional Scanning 
WILEYLWKVPFDFWRGVI 5 >60 
WILEYLWKVPFDFWRGVA 5 >60 
WILEYLWKVPFDFWRGAI 10 >60 
WILEYLWKVPFDFWRAVI 5 >10 
WILEYLWKVPFDFWAGVI 10  
WILEYLWKVPFDFARGVI 10 >100 
WILEYLWKVPFDAWRGVI 10 >100 
WILEYLWKVPFAFWRGVI - >20 
WILEYLWKVPADFWRGVI 5 >10 
WILEYLWKVAFDFWRGVI - >10 
WILEYLWKAPFDFWRGVI 10 >100 
WILEYLWAVPFDFWRGVI 20 >50 
WILEYLAKVPFDFWRGVI 20 >50 
WILEYAWKVPFDFWRGVI - >50 
WILEALWKVPFDFWRGVI - >50 
WILAYLWKVPFDFWRGVI - >50 
WIAEYLWKVPFDFWRGVI - >50 
WALEYLWKVPFDFWRGVI - >50 
AILEYLWKVPFDFWRGVI - >50 
Scrambled peptide (SCR) 
ELDIRLKGFFVWIVWPWY - >50 
 
E1P47 NMR chemical shift assignment in DPC 
micelles  
 
There is very little information about GBV-C E1 envelope 
glycoprotein structure.24 It seems that GBV-C E1 protein 
presents some hydrophobic regions suggestive of 
transmembrane domains (predicted by TMHMM Server v. 2.0, 
Figure 1a), but studies examining the structure of human GBV-C 
E1 proteins by NMR, Cryo-Electron Microscopy and/or X-Ray 
diffraction have not been performed. Our preliminary NMR 
studies with E1P47 peptide in aqueous solution revealed a 1D-
proton spectrum with small and broadened resonances, 
indicative of extensive aggregation, confirming that some 
regions of GBV-C envelope E1 protein and some of its derivative 
peptides should be soluble in a membrane environment.  
Analysis of GBV-C E1 glycoprotein transmembrane topology 
using the TMHMM online server seems to indicate that residues 
1-80 and 172-190 are presented outside while residues 81-103 
and 149-171 are located at the transmembrane region, and 
residues 104-148 are inside (Figure 1a), so the predicted 
location for E1P47 is proximal and/or inside the membrane 
region. Taking into account this information and the amino acid 
composition of E1P47 (two positive and two negative charged 
residues at neutral pH), deuterated dodecylphosphocholine 
(DPC-d38) with a zwitterionic head group similar to that of 
phosphatidylcholine was used as eukaryotic membrane mimetic 
system to perform the subsequent NMR studies.25,26 Due to the 
high hydrophobicity of E1P47, a DPC-d38 concentration high 
enough to allow dissolving the peptide without the observation of 
macroscopic precipitation was used. The effect of DPC 
concentration was evaluated acquiring 1D 1H NMR spectra of 1 
mM E1P47 peptide complexed with DPC at three lipid 
concentrations (50, 100 and 150 mM), observing small chemical 
shift changes and good solubility in this range of DPC 
concentrations (Figure S1, Supplementary Information). E1P47 
resonance assignment is difficult due to overlapping and 
broadening of several peaks in presence of DPC. To make it 
easier and to confirm that the NOEs cross-peaks are correctly 
assigned, we decided to prepare three tryptophan to alanine 
mutants, one for every tryptophan in the E1P47 sequence 
(W139A (Trp-1), W145A (Trp-7) and W152A (Trp-14)). As the 
indole NH protons resonate in a well-resolved, non-overlapping 
low-field region of the spectrum, is easy to assign and 
characterize their NOEs cross peaks to neighbouring residues. 
Comparing the 1H 1D and 1H-1H 2D NMR spectra of the three 
mutants and the parent peptide in DPC aqueous solution (Figure 
S2, Supplementary Information), we could initially assign 
unambiguously the three NH and aromatic indole protons and to 
use these assignments as starting point to identify the rest of 
amino acids (Figures 1b and 1c). The signals attributable to the 
Trp-7 and Trp-14 indole NH protons undergo large upfield shifts 
(Figure 1c) when comparing E1P47 dissolved in DMSO to 
E1P47 in DPC micelles, possibly due to the important 
conformational change after peptide insertion in DPC micelles, 
like changes in the existence and/or nature of the hydrogen 
bonds involving these protons. To assign E1P47 peptide in DPC 
micelles (Figure 1d), 2D 1H-1H NMR spectra were acquired 
using a sample with detergent/peptide molar ratio ~100 at 308 K 
and the assignment was done following the standard sequential 
assignment procedure (Table S2 and Materials and Methods in 
Supplementary Information). Moreover, due to the presence of 
severe overlapping in the aromatic region of 2D 1H,1H spectra, 
we confirmed the assignment of Phe/Tyr/Trp aromatic protons 
by the acquisition of supplementary heteronuclear 2D 1H-13C 
HSQC and HSQC-TOCSY experiments (Figure S3, 
Supplementary Information). This allowed the unambiguous 
assignment of aromatic side chain proton resonances due to the 
improvement in resolution obtained by using the 13C dimension. 
 
E1P47 acquires a helix-turn-helix motive in DPC micelles  
 
Identification of the peptide secondary structure involves 
analysis of characteristic patterns of NOE/ROE cross-peaks 
(Figure S4, Supplementary Information). Table S3 
(Supplementary Information) summarizes the sequential and 
medium-range NOE cross peaks 0bserved for the E1P47 
peptide. However, the presence (or absence) of several cross-
peaks could not be assessed unambiguously due to spectral 
overlap. At the E1P47 N-terminus, sequential and several 
medium-range NOE cross-peaks, indicative of a α-helical 
conformation could be assigned between Trp-1 and Lys-8. In 
addition, several 3-amino acid NOEs αN(i,i+3), N,N(i,i+3) and 
αβ(i,i+3) could also be assigned to this segment, reinforcing the 
adoption of a α-helix conformation. Obvious breaks of (i,i+3) 
NOEs between Trp-7/Pro-10 suggest interruption of helix from 
Lys-8 to Val-9 or Pro-10. Although, Lys-8 and Val-9 NOE 
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correlations are difficult to evaluate due to overlapping with 
aromatic resonances. 
 
 
Figure 1. NMR spectra of E1P47 and its mutants in DMSO and DPC micelles. (a) Representation (using TMPres2D tool,  
http://bioinformatics.biol.uoa.gr/TMRPres2D/) of transmembrane regions of GBV-C E1 protein predicted by TMHMM server 2.0 
(http://www.cbs.dtu.dk/services/TMHMM/). (b) Amide/aromatic region of 1D 1H spectra of E1P47 peptide and its Trp to Ala mutants. (c) E1P47 indole NH region, 
1D 1H spectra acquired in DMSO (below) and DPC micelles (above). (d)  Amide/aromatic region chemical shift assignment of E1P47 1D 1H spectra in DPC 
micelles.  
After Pro-10, several (i,i+3) correlations are in the “ambiguous” 
category because of spectral overlap, and thus cannot be 
confirmed. At the C-terminal region, some of the missing 
correlations for Phe-11 and Asp-12 are originated by peak 
broadening in presence of DPC, although there are some non-
ambiguous αN(i,i+3), N,N(i,i+3) and αβ(i,i+3) correlations that 
could indicate the presence of a second α-helix. These results 
were also confirmed by circular dichroism analysis of E1P47 in 
DPC micelles (Figure S6a, Supplementary Information).   
The experimental information derived from NOEs measurements 
was used as distance restraints to derive a three-dimensional 
structure of the peptide using molecular dynamics simulations. 
Specifically, information from 76 strong and 123 medium NOEs 
was used to impose interatomic distance restrains with intervals 
1.8-2.8 Å and 1.8-3.8 Å, respectively. After imposing all distance 
restrains, the peptide quickly adopts a defined structure in the 
molecular dynamics simulations. However, the structure 
obtained does not completely fulfil a few of the distance restrains, 
independently of the protocol used to impose them. A detailed 
analysis reveals that most of the unfulfilled restrains involve Trp-
14 that also exhibits a distorted side chain. Accordingly, we 
proceeded to study possible incompatibilities around this residue 
by switching on and off diverse restrains involving residue Trp-
14 systematically. This procedure permitted to identify a few 
conformations compatible with the restraints imposed exhibiting 
a common backbone structure but that differ in the orientation of 
Phe-11, Phe-13 and Trp-14 side chains. Figure 2 shows 
pictorially the superimposition of eleven diverse snapshots 
including the different conformations identified during the last 10 
ns of the respective production runs. As can be seen, the 
structure adopted by the peptide can be described as a helix-
turn-helix. Specifically, the N-terminal helix involves residues 1-8, 
whereas the C-terminal helix involves residues 13-18. The two 
helical segments are joined by a loop involving residues Val-9, 
Pro-10, Phe-11 and Asp-12. Interestingly, the structure exhibits 
the side chains of the charged residues aligned forming a spine, 
whereas the side chains of the hydrophobic residues are 
directed in other directions.  
The helical segment at the N-terminus is stabilized by a salt 
bridge between Glu-4 and Lys-8 found in some of the 
conformations, consistent with the weak NOEs observed 
between protons of both side chains. In other conformations 
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Glu-4 interacts with the amine N-terminus via a hydrogen bond, 
consistent with a weak NOE between the Cβ of the former and 
the NH of the latter. Finally, the side chain of Trp-1 is very 
mobile, facing in most of the conformations neighbouring 
residues Ile-1 and Leu-3. 
The presence of the intermediate loop is consistent with several 
strong-medium NOE correlations between Val-9 and Phe-13 
backbone and side chains protons that confirm that Val-9/Phe-
13 residues are not connected by a α-helix. Specifically, if Val-9 
were involved in a regular α-helical conformation, the αβ(i, i+4) 
distance will be around 5.0-7.0 Å, showing very weak 
NOEs.27,28 In contrast, in our experiments suggest that this 
distance is shorter (strong-medium NOEs). Furthermore, one of 
the Val9 γCH3 groups is much shielded (it appears at lower 
chemical shift than expected), confirming that these CH3 
protons are near aromatic groups. Finally, another indication that 
the Phe-13 ring is interacting with Val-9 (i − 4) is the up-field 
displacement of the chemical shift of Val-9 α -CH atom (Table 
S2, 3.85 ppm). In a few of conformations the side chains of Tyr-
5 and Phe-11 exhibit distances of ~5Å to the Pro-10 ring, 
respectively forming a sandwich stabilized by quadrupole-
quadrupole interactions. Interestingly, the motif Tyr-Pro-Tyr/Phe 
has been found in peptides with structures involving a β-turn 
secondary motif.29,xx  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Superposition of the eleven conformations adopted by E1p47 in 
DPC micelles identified from MD simulations using diverse distance restrains 
derived from the NMR studies, showing two alternative conformations. 
 
At the C-terminus, the entire set of conformations exhibit a salt 
bride between residues Asp-12 and Arg-15. Moreover, Asp-12 is 
simultaneously involved in a salt bridge with Lys-8 in most of the 
conformations, stabilizing the relative orientations of the two 
helices of the helix-turn-helix motif. The side chain of Trp-14 
adopts two conformations. In one it appears close to Val-9 and 
Phe-13, consistent with several inter-residue strong NOEs. This 
conformation is stabilized by a quadrupole-quadruple interaction 
between the two aromatic side chains of Phe-13 and Trp-14.30 
Actually, there are several NOEs between the side chains of 
these residues that permit to characterize the relative orientation 
of the aromatic rings. Further confirmation is the observation, for 
the mutant W152A, that the resonances corresponding to Phe-
13 aromatic ring disappeared (moving to lower field is 
suspected) (Figure S5, Supplementary Information). This lack of 
a shielding effect could be related to the disappearance of the 
electronic effect in the chemical shift of the relative orientation 
between Phe-13/Trp-14 and validate the presence in the wild 
type peptide of a specific packing that produces the shielding of 
aromatic Phe-13 resonances in presence of Trp-14.31 In the 
other conformation, Trp-14 side chain moves away from Phe-13 
to get in proximity to Phe-11, as supported by medium and weak 
NOEs between the two residues. Finally, the C-terminus is very 
mobile showing diverse conformations. 
The experimental information derived from NOEs measurements 
was used as distance restraints to derive a three-dimensional 
structure of the peptide using molecular dynamics simulations. 
Specifically, information from 76 strong and 123 medium NOEs 
was used to impose interatomic distance restrains with intervals 
1.8-2.8 Å and 1.8-3.8 Å, respectively. After imposing all distance 
restrains, the peptide quickly adopts a defined structure in the 
molecular dynamics simulations. However, the structure 
obtained does not completely fulfil a few of the distance restrains, 
independently of the protocol used to impose them. A detailed 
analysis reveals that most of the unfulfilled restrains involve Trp-
14. Accordingly, we proceeded to study possible 
incompatibilities around this residue by switching on and off 
diverse restrains systematically. This procedure permitted to 
identify two different conformations compatible with the 
restraints imposed that exhibit a similar backbone structure but 
that differ in the orientation of Phe-11 and Arg-15 side chains. 
Figure 2 shows pictorially the superimposition of a few 
snapshots involving the two conformations identified during the 
last 10 ns of the respective production runs. As can be seen, the 
structure adopted by the peptide in any of the two conformations 
can be described as a helix-turn-helix. Specifically, the N-
terminal helix involves residues 1-8, whereas the C-terminal 
helix involves residues 12-18. The two helical segments are 
joined by a loop involving residues Val-9, Pro-10 and Phe-11. 
Interestingly, the structure exhibits the side chains of the 
charged residues aligned in one side of the peptide, whereas the 
side chains of several aromatic residues including Trp-1; Tyr-5, 
Phe-13 and Trp-14 are facing the opposite side. The two 
conformations exhibit a similar backbone structure, although 
they present a different scheme of inter-residue interactions at 
the C-terminus. The helical segment at the N-terminus is 
stabilized by a salt bridge between Glu-4 and Lys-8, consistent 
with the weak NOEs observed between protons of both side 
chains. In addition, the interaction between Trp-1 and Tyr-5 
found in the MD derived structure is supported by strong to 
medium intra amino acid NOEs between aromatic protons and 
their backbone α/β protons.  
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Figure 2. Superposition of the two conformations adopted by E1p47 in DPC 
micelles identified from MD simulations using diverse distance restrains 
derived from the NMR studies, showing two alternative conformations. 
 
The presence of the intermediate loop is consistent with several 
strong-medium NOE correlations between Val-9 and Phe-13 
backbone and side chains protons that confirm that Val-9/Phe-
13 residues are not connected by a α-helix. Specifically, if Val-9 
were involved in a regular α-helical conformation, the αβ(i, i+4) 
distance will be around 5.0-7.0 Å, showing very weak NOEs.27,28 
In contrast, in our experiments suggest that this distance is 
shorter (strong-medium NOEs). Furthermore, one of the Val9 
γCH3 groups is much shielded (it appears at lower chemical 
shift than expected), confirming that these CH3 protons are near 
aromatic groups. Finally, another indication that the Phe-13 ring 
is interacting with Val-9 (i − 4) is the upfield displacement of the 
chemical shift of Val-9 α -CH atom (Table S2, 3.85 ppm). 
At the C-terminus, one of the conformations exhibits a salt bride 
between residues Asp-12 and Arg-15, whereas in the other the 
Arg-15 forms a hydrogen bond with the side chain of Phe-11.29 
The former conformation permits a disposition of the side chain 
of Trp-14 close to Phe-13 and Val-9, consistent with several 
inter-residue strong NOEs. In contrast, the other conformation 
permits the side chains of Phe-11 and Arg-15 to be in a 
hydrogen bond distance at the cost of separating the side chain 
of Trp-14 from those of Phe-13 and Val-9. The proton-aromatic 
ring hydrogen bond interaction is consistent with the observation 
of NOE cross peaks compatible with the proximity between Phe-
11 aromatic protons and Arg-15 side chain protons, but only 
Phe-11 3H-5H/Arg-15 cross peaks are unambiguous and do not 
overlap with other resonances (the integral cross peaks 
correspond to weak and very weak NOEs). Moreover, residues 
Phe-13 and Trp-14 at C-terminus may reinforce helix stability 
through quadrupole-quadrupole interactions between the two 
aromatic rings since they show up at a distance of ~5Å, typical 
for this type of interaction.30 Actually, there are several NOEs 
between Phe-13 and Trp-14 that allow to characterize the 
relative orientation of the aromatic rings. Further confirmation is 
the observation, for the mutant W152A, that the resonances 
corresponding to Phe-13 aromatic ring disappeared (moving to 
lower field is suspected) (Figure S5, Supplementary Information). 
This lack of a shielding effect could be related to the 
disappearance of the electronic effect in the chemical shift of the 
relative orientation between Phe-13/Trp-14 and validate the 
presence in the wild type peptide of a specific packing that 
produces the shielding of aromatic Phe-13 resonances in 
presence of Trp-14.31 An important point to mention is that the 
peptide bond between Val-9 and Pro-10 adopts a cis 
conformation in both structures. However, the conformation that 
exhibits a salt bridge between Asp-12 and Arg-15 can also be 
attained with the peptide bond in a trans conformation.  
 
E1P47 Location in DPC micelles: diffusion NMR 
and evaluation of the effects of paramagnetic 
relaxation agents  
 
Pulsed-field-gradient nuclear magnetic resonance (PFG-NMR) 
has been previously used to obtain the hydrodynamic size of 
lipid-complexedpeptides.32,33 To confirm the binding of E1P47 to 
DPC micelles, the translational diffusion coefficients for E1P47 
and DPC in the binary complex were measured using this 
technique (Table 3). The aggregation number of DPC monomers 
per micelle in the literature varies between 56 and 80, 
depending on the biophysical technique and the experimental 
conditions used.34-36 Taking into account these values and the 
DPC:peptide ratio (100:1 50mM:0.5mM) used, we estimated that 
we had enough DPC for the insertion of all E1P47 peptide 
molecules in the micelles. NMR measurements showed that the 
value of self-diffusion coefficients obtained for E1P47 is in the 
expected range for a peptide of similar length associated to 
micelles (Table 3),.25,37 We were not able to measure the value 
of the free E1P47 peptide self-diffusion coefficient due to its 
aggregation in aqueous buffered media (without lipid) and 
without this value we couldn’t calculate the partition coefficient of 
E1P47 in micelles. However, taking into account that the peptide 
is insoluble in water, we expect that most of the peptide is bound 
to DPC micelles. As control for viscosities changes due to the 
different composition in samples A and B (Table 3), we 
measured the diffusion coefficient for 4,4-dimethyl-4-
silapentane-1-sulfonic acid (DSS) proton resonance. The self-
diffusion coefficient measured for DPC micelles is in agreement 
with literature values.38 The results for DPC methylene chain 
resonances in the E1P47/DPC sample, with a  10% decrease 
in the lipid self-diffusion coefficient in presence of E1P47 peptide 
(from 8.43 to 7.52x10-11 m2/s) could indicate a small increase in 
the micelle hydrodynamic radius (RH) that is associated to an 
increase in the lipid aggregation number25 or the reduction of 
DPC free fraction39,40 in presence of the peptide. 
The diffusion NMR results confirm that E1P47 peptide is 
associated to DPC micelles, but not how is located in them (lying 
on the surface or immersed partially or completely inside the 
micelle?). To determine the position of E1P47 peptide in DPC 
micelles, paramagnetic lipid compounds wereadded. The 
paramagnetic species enhance the relaxation rates for nuclei 
close to the paramagnetic agent and the measurement of the 
changes in resonances amplitudes (or line width) allows a semi-
quantitative or qualitative analysis.41,42 As paramagnetic lipids, 
the spin ½ doxyl group attached to different positions of stearic 
acid, 5-doxyl (nitroxide moiety located near the phosphate 
group) and 16-doxyl (nitroxide moiety located near the micelle 
center) were used.43 
 
 
 
Table 3. Translational diffusion coefficient measured by NMR spectroscopy for 
peptide samples in DPC (A,B and C) and DPC micelles (D). 
 D (10-11 m2s-1) RSSa 
Sample A: E1P47+DPC (0.5:50 mM) 
E1P47b 5.68 ± 0.04 4.00x10-4 
E1P47c 5.73 ± 0.03 5.25x10-5 
E1P47d 5.71 ± 0.06 9.48x10-4 
E1P47e 5.83 ± 0.07 4.00x10-4 
DPCf 7.52 ± 0.02 8.30x10-5 
DSS 30.70 ± 0.01 1.25x10-4 
Sample B: 
E1P47+FP23+DPC 
(0.5:0.5:50 mM) 
E1P47b  5.65 ± 0.07 1.10x10-3 
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E1P47c,g 6.51 ± 0.10 4.00x10-4 
E1P47d,g 6.38 ± 0.05 6.10x10-3 
E1P47e,g 6.83 ± 0.02 4.40x10-4 
DPCf  7.51 ± 0.03 1.00x10-4 
DSS 31.92 ± 0.01 1.34x10-3 
Sample C: 
E1P47+FP23+DPC 
(0.5:0.5:100 mM) 
E1P47b  5.68± 0.07 1.10x10-3 
E1P47c,g 6.10 ± 0.03 1.22x10-5 
E1P47d,g 6.07 ± 0.10 5.00x10-4 
E1P47 e,g 6.67 ± 0.04 5.00x10-4 
DPCf  6.80 ± 0.04 3.00x10-4 
DSS 21.76 ± 0.01 1.15x10-3 
Sample D: DPC 50 mM  
DPCf  8.43 8.85x10-5 
DSS 31.16 2.43x10-4 
[a] RSS (Residual Sum of Squares). [b] E1P47 peptide Trp-14 side chain 
region 7.45-7.52 ppm. [c] E1P47 peptide methyl region 0.93-0.81 ppm. [d] 
E1P47 peptide W145 side chain region 7.23-7.26 ppm. [e] E1P47+FP23 Phe 
region 7.23-7.16 ppm. [f] DPC region 1,26-1,14 ppm. [g] Resonances from 
E1P47+FP23 
 
A water-soluble paramagnetic metal salt (GdCl3, spin 3/2) was 
also tested, allowing characterizing the residues that are lying 
outside the DPC micelles. Upon addition of 3 mM 5-doxyl stearic 
acid (5-DSA) to E1P47/DPC micelles (ratio 5-DSA:DPC ~ 1:70, 
one spin-label per micelle molecule), we observed important 
chemical shift changes and an increase in the intensity of most 
backbone amide resonances in the 1D 1H spectra (amide 
resonance for Glu-4, Tyr-5, Phe-11, Asp-12, Phe-13, Trp-14 and 
Arg-15; see Figure S7a, Supplementary Information), whereas 
aromatic resonances showed a small decrease in intensity and 
very small broadening. This trend is also observed in the 2D 
NOESY 1H-1H spectra (Figure S7b, Supplementary Information). 
These results imply that the presence of the 5-DSA spin-label 
has some influence on the conformation of E1P47 bound DPC. 
Qualitatively, the resolution improvement of overall cross-peaks 
in the 2D NOESY spectra seems to indicate that the presence of 
the nitroxide atoms near the DPC phosphate group could 
destabilize a little the interaction between the peptide and the 
lipid, improving the peptide mobility inside the micelles. Also, this 
is an indirect observation that the most part of the peptide amide 
groups is at the level of DPC phosphate moiety in the micelle. 
The Gd3+ paramagnetic cations are located in the aqueous 
phase, at the vicinity of the cationic head group of DPC and, are 
expected to cause selective broadening of residues exposed to 
the solvent  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Effect of paramagnetic compounds in NMR spectra of 2 mM E1P47 
peptide in 200 mM DPC-d38 micelles, 10 mM sodium phosphate, pH=6.2 and 
10% D2O. (a) 1D 1H NMR spectra with 0 and 3.4 mM of 16-DSA; (b) 2D 1H,1H-
NOESY spectra with 0 and 3.4 mM of 16-DSA; (c) 1D 1H NMR spectra with 0 
and 0.4 mM of GdCl3; (b) 2D 1H,1H-NOESY spectra with 0 and 0.4 mM of 
GdCl3. 
 
or close to the water-micelle interface (mainly affect the proton 
and carbon signals from the methylene groups close to the 
choline head group). Addition of 0.4 mM Gd3+ led to the uniform 
retention of the 70% of the E1P47 resonance intensities, 
indicating that E1P47 was not exposed to the solvent but 
embedded in the DPC micelles (Figure 3c-d and Figure S8a, 
Supplementary Information). Using 16-DSA, with a 16-DSA/DPC 
ratio of ~ 1:70, the resonances of Trp-7 and Val-9 decreased to 
10-20% of the initial intensity (Pro-10 was not observed due to 
the lack of amide proton and resonances from Lys-8 are 
overlapped with other resonances), and those corresponding to 
residues located on both sides of these amino acids presented a 
reduction in intensity between a 40 to 70% (Figures 3a-b and 
Figure S7, Supplementary Information). The results obtained 
with 16-DSA suggest that E1P47 is inserted inside the DPC 
micelles, with the most quenched residues located toward the 
micelle core centre (Trp-7, Val9 and Pro-10). The most charged 
residues (Glu-4, Asp-12 and Arg15) present intermediate 
quenching level (between 40 and 75%), in agreement with the 
conformations identified by MD analysis. The effects observed 
by 5-DSA, 16-DSA and GdCl3 and the observation of 
intermolecular NOE cross peaks between Glu-4 and Asp-12 side 
chain protons with methyl’s from DPC choline head group (data 
not shown), indicate that E1P47 peptide is inside the micelle, 
likely lying nearly parallel to the surface, with negative charged 
side chains oriented to choline head group and the hydrophobic 
residues pointing to the micelle core (Figure S8b, Supporting 
Information). 
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Interaction between E1P47 and its viral target, 
FP23 
 
One of the known requirements of HIV-1 virus-cell fusion is the 
formation of a pre-fusion intermediate of the trimeric gp41 
glycoprotein that folds into a six helical bundle structure leading 
to the apposition of the viral and cellular membrane.44,45 In the 
prefusion intermediate the N-terminal region of gp41 (FP) is 
inserted into the cell membrane, while its transmembrane region 
(TM) is anchored to the viral membrane. The folding of N- and 
C- terminal heptad repeats of gp41 to form a triple stranded 
coiled-coil is responsible for lowering the free-energy barrier 
required for viral and target cell membrane fusion. After the 
confirmation that E1P47 is structured as a helix-turn-helix lying 
inside a membrane-mimicking environment, we sought to 
validate and characterize the interaction between E1P47 and 
FP23 peptides in DPC micelles. NMR chemical shift has been 
used as a probe to study protein-protein (or peptide-peptide) 
interaction and to map the binding site.46,47 The association of 
E1P47 and FP23 in the presence of DPC micelles was studied 
by titrating E1P47 in DPC micelles with increasing amounts of 
FP23 (previously dissolved in DMSO) until 1:1 ratio and 
monitoring the changes by acquisition of consecutive 1D 1H 
NMR experiments (Figure S9, Supplementary Information). 
 
FP23 peptide hydrophobicity limited the working concentration 
range, so using low E1P47 peptide concentration in 
DPC/HEPES buffer to avoid Fp23 aggregation and precipitation 
during titration was necessary.48,49 Chemical shift changes for 
E1P47 amide groups of Leu3, Glu4, Asp12, Phe13, Trp-14 and 
Arg-15, the NH proton from indole side chain of Trp-1, Trp-7 and 
Trp-14 and the aromatic protons of Tyr-5, Trp-7, Phe-11, Phe-13 
and Trp-14, were observed. In addition, line broadening was 
observed for some peaks (as 3,5H for Tyr-5 or 2,6H Phe-11, 
Figure S9b). We initially attribute these chemical shift/lineshape 
variations to a change of conformational dynamics within E1P47 
due to peptide-peptide interaction and not a consequence of a 
large increase in correlation time after FP23 addition (validation 
by Diffusion NMR experiment is presented onwards). These 
changes are more easily followed using the tryptophan NH 
indole proton. In Figure 4a, the variations in E1P47 three 
tryptophan’s indole region upon titration with FP23 are shown. 
Due to E1P47 hydrophobicity and affinity for DPC, we expected 
that nearly all E1P47 molecules were inserted in DPC micelles 
and micellar E1P47 didn’t experience rapid exchange with 
residual free peptide in solution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Study of the interaction between the peptides E1P47 and HIV-1 
FP23.  The association of E1P47 with FP23 was characterized by titration of 
previously pre-formed E1P47/DPC complexes with increasing amounts of 
FP23 (from 1:100 total peptide:DPC to 1:50 total peptide:DPC, in 20 mM 
HEPES, pH=6.2, 300K). 
 
So, in the titration (E1P47 concentration nearly constant) the 
contribution of mixed fast-intermediate regime dynamic 
processes could not be discarded (E1P47 conformational 
change upon FP23 binding, change of E1P47 interaction with 
micelles upon FP23 binding and exchange of E1P47 between 
micelles). The resonance for E1P47 Trp-14 NH indole 
broadened until mid-titration (1:0.51 E1P47:FP23) and then 
recovered around 1:1 ratio (Figure 4b).  In this case, the initial 
broadening followed with the narrowing of E1P47 resonances for 
FP23 ratios >0.5 is compatible with mixed fast/intermediate 
exchange processes on the NMR time scale. Analysis of NMR 
lineshapes can yield information on the affinities/kinetics of 
ligand binding but,50-51 due to the difficulties to stablish a simple 
model, the calculation of a Kd for E1P47-Fp23 is complex and 
not attempted. To validate the formation of the complex between 
the two peptides in DPC micelles, the inverse titration 
experiments, maintaining constant FP23 concentration 
(previously dissolved in DPC-d38 micelles) and adding 
increasing amounts of E1P47 until 1:1 ratio, were also acquired. 
The known chemical shift assignment of FP23 in DPC micelles 
was used for comparison purposes17,19,52,53 and was 
complemented by acquiring the 2D 1H-1H NOESY of FP23 
peptide in equivalent conditions (same peptide:DPC ratio, pH 
and temperature) that for our titration experiments. Using 2D 
NOESY spectra and literature values, we could assign some of 
the FP23 residues that experienced chemical shift changes after 
E1P47 addition. Due to concentration limitations (use of small 
concentration to avoid peptide aggregation) and the presence of 
overlapped E1P47/FP23 resonances in FP23 titration with 
E1P47, only the chemical shift variation of a few FP23 
resonances was identified unambiguously. In particular, we 
could observe chemical shift changes for the amide groups of 
Gly-3, Ile-4, Gly-5, Leu-7, Phe-11 and aromatic Phe-8 and/or 
Phe-11 protons (Figure S10, Supplementary Information).  
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Figure 5. The association of FP23F8W 
(AVGIGALWLGFLGAAGSTMGAAS) with E1P47 was characterized by 
titration of previously pre-formed FP23 F8W/DPC complexes with 
increasing amounts of E1P47 (1:100 total peptide:DPC to 1:50 total 
peptide:DPC, in 20 mM HEPES, pH=6.2, 300K). 
 
In the two conditions used for FP23 titration (different buffer, 
initial FP23 concentration and FP23:DPC ratio), we observed a 
progressive broadening of FP23 resonances when increasing 
E1P47 amounts (Figures S10 and S11, Supplementary 
Information). It is known that for low concentration 
peptide:detergent ratios ( 1:50, 0.02 or lower), lysine or 
aspartic-tagged FP23 peptide is in a helical conformation from 
Ile4 to Ala15.17,19,53 For unmodified FP23 peptide and high FP23 
peptide:detergent ratios (1:10, 2 mM FP23), aggregation has 
been observed and, using CD and FTIR studies, that has been 
associated to the presence of -conformation.4 Considering that, 
during E1P47:FP23 titrations, the total peptide:detergent ratio is 
in the low range and that we are working at low FP23 
concentration (~ 0.2-0.3 mM),  we propose that the NMR 
observed line broadening is not originated by FP23 aggregation 
but for an intermediate exchange binding process. To further 
validate these results, we repeated the titration using a FP23 
mutant that contains a Tryptophan in position 8 instead of 
Phenylalanine (F8W). This analogue conserves fusogenic 
activity and adopts the same conformations in solution than the 
wild type peptide.54 The advantage of this mutant is that the 
tryptophan resonance could be followed unambiguously. F8W 
FP23 aromatic and indole group region of the E1P47 titrated 
NMR spectra are displayed in Figure 5. A progressive chemical 
shift change and broadening of the Trp-8 indole NH resonance 
were observed. In this case, the maximum broadening didn’t 
happen for F8W FP23:E1P47 1:0.5 ratio (in contrast of E1P47 
titration with FP23), perhaps associated to different koff  for 
complexed species. 
The simultaneous presence of both peptides in DPC micelles 
was evaluated by diffusion NMR (Table 3). The measurement by 
NMR of the diffusion coefficient for the E1P47+FP23/DPC 
samples had two objectives; to confirm that both peptides could 
be inserted in the micelles at the same time and that the 
resonance broadening observed during titration is not originated 
with a decrease on peptide correlation time (due to the increase 
of the aggregation number of DPC in micelles in presence of the 
two peptides, due to the intermolecular association of DPC 
micelles or/and peptide aggregation). For the ternary complex 
(sample B, Table 3), the diffusion coefficient of DPC remains 
unaltered, indicating that micelles aggregation number/size or 
DPC free fraction doesn’t change significantly after FP23 
addition. The diffusion coefficient of several E1P47 resonances 
showed a small increase in those regions with overlapped FP23 
and E1P47 signals (samples B and C, entries c, d and e 
corresponding to overlapped Leu/Ile/Val methyl’s and Phe 
aromatic protons from both peptides). Only the value for region b 
corresponds to E1P47 pure coefficient diffusion in micelles. This 
value remained constant in the three samples (A, B and C), 
regardless of the composition. Due to resonance overlap, it was 
not possible to measure the diffusion coefficient of FP23 in 
DPC+E1P47 complex, but the peak e (Table 3) contains mainly 
contributions for FP23 peptide and the measured diffusion 
coefficient, 6.83x10-11 m2/s (300K, 0.5 mM) is very similar to the 
diffusion coefficient previously measured for FP23 in DPC 
micelles (7.0x10-11 m2/s, 298K, 0.5 mM FP23),52 confirming that 
FP23 peptide also associates with DPC micelles in presence of 
E1P47 peptide. For sample B, FP23 calculated bound molar 
fraction is 0.91 (additional analysis in Material and Methods, 
Supporting Information), so we hypothesize that the contribution 
of the free FP23 component (0.09 molar fraction) increases his 
observed diffusion coefficient in comparison to the value for 
E1P47 peptide. The distribution/number of side chain charges 
and hydrophobic groups seems determinant for peptide binding 
to micelles and E1P47 and FP23 peptides are very different in 
those features (Figure S12, Supporting Information).55-57 
According to MD calculations, Our our inhibitor , -E1P47 peptide, 
- contains clustersexhibits a spine of charged residues aligned in 
one side of the molecule, with the and at least 4 aromatic 
hydrophobic residues pointing in on the oppositediverse  side 
directions opposite to the spineaccording to MD, with that 
confers a structure highly favourable for its the whole insertion in 
DPC micelles. Besides, our diffusion NMR results confirm that 
E1P47 is nearly fully bound to DPC micelles. We note that the 
micelles are much larger than the peptides; thus the 
accommodation of several peptide molecules in one micelle is 
possible without a size/aggregation number change in micelles. 
Taking into account the known DPC aggregation number (65-80) 
and that the E1P47 diffusion coefficients remains the same in 
presence of FP23, our results suggest that both peptides could 
coexist in the same micelle without a significant change in 
micellar size and that the broadening observed during NMR 
titrations is originated by FP23/E1p47 interaction.  
On the other hand, to confirm the specificity of the E1P47-FP23 
interaction, we performed a titration (addition of FP23 to SCR in 
DPC) and measured SCR diffusion coefficients in DPC 
with/without FP23, using the same control peptide that in cellular 
assays (SCR, Table 2). The results are shown in Figure S13 
(Supporting Information) and are according to the fact that SCR 
and FP23 could not bind simultaneously to lipid micelles due to 
the much higher affinity of FP23 to membrane environment. In 
addition, the secondary structure of SCR obtained by circular 
dichroism agrees well with a β-strand conformation that can 
explain the absence of any kind of anti-HIV-1 activity for this 
peptide sequence.  
Some authors have described that FP and transmembrane 
domain (TM) are in close proximity during viral fusion suggesting 
that the N-terminal domain of gp41 interacts with the TM and/or 
with the membrane proximal external region (MPER) 
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contributing energy to the membrane fusion reaction.58,59 
Although the NMR spectroscopy study on the structure and 
dynamics of the homotrimeric gp41 complex reconstituted in 
DPC micelles carried by the group of Bax excluded a significant 
interaction between FP and TM,60 recent studies on the 
intermediary steps of the fusion process demonstrates that 
trimerization of HIV-1 gp41 ectodomain bound to 
dodecylphosphocholine micelles requires the presence of both 
the fusion peptide proximal region (FPPR) and the MPER.61 The 
structural study carried out by Buzon demonstrated that most of 
the conserved residues of MPER are hydrophobic residues that 
contribute to hydrophobic interactions with FPPR being these 
domains critical for stabilizing the six-helix bundle formation in a 
detergent environment.62 The structure of the MPER in DPC 
micelles is characterised by a helix-hinge-helix motif with the 
aromatic residues buried on the membrane.63 The disruption of 
the structural motif by double alanine mutations of MPER 
reduced the fusion activity and viral entry indicating that the 
structural conformation of this region is relevant to maintain the 
fusogenic activity of the protein.64 Comparatively, the structure in 
DPC micelles of E1P47 peptide is very similar to the MPER 
region of HIV-1 gp41. Our results demonstrated that this 
conformation is also important for maintaining the inhibitory 
activity of the peptide since the change of the helix-turn-helix by 
a β-sheet conformation, demonstrated by CD on the scrambled 
sequence in DPC micelles (Figure S6, Supporting Information), 
determines the loss of inhibition activity. Based on this 
background and considering the structural homology between 
the E1P47 peptide and the MPER, the inhibition mechanism of 
the E1P47 could also be related to the impairment of the 
interaction of the FP peptide with other membrane active 
domains of HIV-1 gp41, such as MPER, that are pivotal for the 
stabilization of the fusion active molecular structure. 
Thus, the interaction of E1P47 inhibitor with the FP at the 
membrane might block further gp41 refolding required for 
membrane fusion either avoiding the clustering of the FP on the 
membrane and/or hindering the interaction of FP with MPER/TM 
regions. 
Conclusions 
NMR data reveal that E1P47 peptide forms a helix-turn-helix in 
zwitterionic micelles. Antiviral structure-activity studies confirm 
the importance of some structural elements in E1P47 anti-HIV-1 
potency, like the N-terminal α-helix, the Pro-10 in the hinge 
region and the Asp-12 in the second helix motif. NMR 
measurement of E1P47 diffusion coefficient and the effect of 
paramagnetic compounds on E1P47 NMR spectra indicate that 
E1P47 is soaked inside DPC micelles, lying parallel to the 
micelle surface. Besides, our results show the first evidence that 
the interaction between E1P47 and its viral target (FP23) takes 
places at membrane level. We propose that E1P47 could 
interfere with those domains in HIV-1 that are critical for 
stabilizing the six-helix bundle formation in a membranous 
environment and consequently, inhibit the viral entry.Main Text 
Paragraph. 
Experimental Section 
Experimental Details. 
Computational studies 
 
Restrained molecular dynamics was used to provide a three-
dimensional structure of E1P47 compatible with the structural 
information provided by NMR spectroscopy. For this purpose, 
we used as starting structure the extended conformation of the 
peptide with its N-terminus charged and the C-terminus 
amidated. Side chains of Glu-4, Lys-8, Asp-12 and Arg-15 were 
considered as charged. The environment of the peptide was 
simulated using a generalized Born model (Anandakrishnan et 
al., 2015) with an intermediate dielectric constant (ε=32.7). 
Subsequently, 10 ns restrained molecular dynamics simulations 
were performed using distance constrains deduced from 76 
strong and 123 medium NOEs signals and imposing a 1.8-2.8 Å 
and 2.8-3.8 Å distance restriction with a force constant of 1 kcal 
mol-1 Å-2 to the corresponding atoms involved. Since the 
simulation including all the restrictions dis not provide 
satisfactory results, we carried out two simulations lifting part of 
the restrains on the Trp-14 residue. In the first simulation, all the 
retrictions regarding the Trp-14 were lifted and for the second, 
only the medium intensity restrictions were lifted. A 2fs 
integration step was used for the molecular dynamics runs after 
constraining all the bonds involving hydrogen atoms using the 
SHAKE algorithm (Miyamoto et al., 1992).  
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